A. V. Sergeev

A. V. Sergeev

Auto-generated profile, based on publicly available information

A. V. Sergeev

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
GTG. R. Tabeeva
G. R. Tabeeva
VOV. V. Osipova
V. V. Osipova
EFE. G. Filatova
E. G. Filatova
YAYu. E. Azimova
Yu. E. Azimova
AAA. V. Amelin
A. V. Amelin
VPVladimir Parfenov
Vladimir Parfenov
The Russian experts’ guidelines on evaluation and treatment of medication-overuse headache are based on evidence-based medicine, the latest revision of the International Classification of Headache Disorders. Basic information about epidemiology, risk factors, pathophysiological mechanisms, evaluation, and the most effective pharmacological drug and non-pharmacological approaches to managing patients with medication-overuse headache are presented.

16 February 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
GTG. R. Tabeeva
G. R. Tabeeva
EFE. G. Filatova
E. G. Filatova
AAA. V. Amelin
A. V. Amelin
VOV. V. Osipova
V. V. Osipova
AAA. R. Artemenko
A. R. Artemenko
VPVladimir Parfenov
Vladimir Parfenov
Migraine is a chronic neurological disorder that is associated with considerable disadaptive effect on patients. Despite the development of pharmacotherapy strategies for migraine, only one third of patients are satisfied with their overall treatment. Many migraine patients turn to complementary and alternative medicine (CAM), which is not usually considered a part of conventional medicine and is not always evidence-based. In practise, however, they are often used to improve the effectiveness of standard therapy or to provide alternative treatment. In addition, in CAM methods, the patient is actively involved in the choice of treatment strategies, and they have good adherence. The basic principles and approaches of CAM are increasingly being introduced into clinical practise. This review discusses the principles of CAM in the treatment of migraine as a holistic approach using lifestyle strategies and selected non-pharmacological treatments that have been shown to be effective and rational.

1 May 2023 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
GTG. R. Tabeeva
G. R. Tabeeva
AAA. V. Amelin
A. V. Amelin
LALeila Rinatovna Akhmadeeva
Leila Rinatovna Akhmadeeva
ADAlexey B. Danilov
Alexey B. Danilov
ODO. B. Doronina
O. B. Doronina
EFE. G. Filatova
E. G. Filatova
On December 24, 2022, in Moscow an interdisciplinary Council of Headache Experts, held under the auspice of the interregional public organization “Russian Society for the Study of Headache”, discussed the key problems of effective treatment of a migraine attack and the possibilities of a specific drug Kaporiza® (rizatriptan). Despite the development of strategies for the relief of migraine attacks and the effectiveness of triptans as first-line therapy, the choice of a specific drug in accordance with the individual clinical profile of the patient is difficult due to the existence of drugs in various forms (standard tablets, oral dispersible forms, injections, nasal sprays, rectal suppositories). Rizatriptan in the form of an orally dispersible tablet (ODT) has a number of advantages: high bioavailability, fast onset of action, and ease of use. Therefore, Kaporiza® (rizatriptan ODT) may be recommended as a priority therapy for all migraine patients who prefer the dispersible tablet form and who experience symptoms of nausea and vomiting, as well as for patients who have experience of poor efficacy and/or poor tolerability of other triptans. The Expert Council recommends to include rizatriptan ODT in the next edition of the clinical guidelines for the diagnosis and treatment of migraine as a first-line agent with Level A evidence.

25 October 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
ASA. V. Sergeev
A. V. Sergeev
GTG. R. Tabeeva
G. R. Tabeeva
EFE. G. Filatova
E. G. Filatova
AAA. V. Amelin
A. V. Amelin
LALeila Rinatovna Akhmadeeva
Leila Rinatovna Akhmadeeva
KSK. V. Skorobogatykh
K. V. Skorobogatykh
This consensus reviewed the main current issues of clinical application and integration into everyday practice of a new targeted preventive therapy for migraine using monoclonal antibodies (mAbs) to the calcitonin gene related peptide (CGRP) ligand or receptor. These recommendations are based on current scientific and clinical studies and an analysis of the results of several years of clinical use. The main purpose of the consensus is to assist practitioners in prescribing effective prophylactic treatment of migraine using anti-CGRP mAbs and to improve care for patients with various forms of the disease.

19 October 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
EGE. A. Guziy
E. A. Guziy
ASA. V. Sergeev
A. V. Sergeev
GTG. R. Tabeeva
G. R. Tabeeva
Chronic migraine (CM) affects three out of every hundred people. As the frequency of attacks increases, so does the frequency of painkillers usage, and 85% of patients with CM are also diagnosed with medication overuse headache (MOH).Objective: to investigate the efficacy of preventive therapy of CM with or without MOH.Material and methods. The study involved 117 patients with CM and MOH (group 1) and 23 patients with CM without MOH (group 2), patients were examined at the initial visit and after 3 and 9 months of follow-up. All patients in the 1st group (CM+MOH) received a 7-day "detoxification" therapy. Patients in both groups were given an educational and information session on the type of their diagnosis, treatment methods and lifestyle correction. The choice of a preventive treatment in both groups was based on the current clinical recommendations, algorithms of modern international guidelines, concomitant pathology, the presence of contraindications in a particular patient, tolerability, as well as territorial and economic factors.Results. A positive effect was found in both groups, regardless of the presence of MOH. The lack of significant differences between the groups of CM with/without MOH is probably due to the use of "detoxification" therapy and the cessation/restriction of the use of the drug of abuse in all patients with CM and MOH, although a more pronounced positive dynamics is observed in patients of the 2nd group (CM without MOH), which in turn emphasizes the severity of the disease, the greater disability and the poorer prognosis for response to preventive treatment in the presence of MOH. It was found that one third of patients in the study favored monoclonal antibodies (mAbs) due to convenience, rapid onset of action and tolerability. In the group of patients with MOH, the best results were obtained when using injection methods of treatment (anti-CGRP mAbs, botulinum therapy) or when using combined therapy compared to monotherapy with venlafaxine or topiramate.Conclusion. All first-line drugs for the CM prophylactic treatment according to the clinical guidelines of the Ministry of Health of Russia are clearly effective, including cases with both CM and MOH. The use of combined therapy in CM with/without MOH can be effective even with a low initial response to one of the monotherapies.

1 January 2018 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Open access
PDF file
GTG. R. Tabeeva
G. R. Tabeeva
AAA. V. Amelin
A. V. Amelin
LAL. R. Akhmadeeva
L. R. Akhmadeeva
ADAlexey B. Danilov
Alexey B. Danilov
ODO. B. Doronina
O. B. Doronina
ESE. A. Shestel
E. A. Shestel
Medical article медицинская статья